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DX5+NKT cells display phenotypical and
functional differences between spleen and liver
as well as NK1.1-Balb/c and NK1.1+ C57Bl/6 mice
Jens M Werner, Elisabeth Busl, Stefan A Farkas, Hans J Schlitt, Edward K Geissler and Matthias Hornung*
Abstract
Background: Natural killer T cells represent a linkage between innate and adaptive immunity. They are a
heterogeneous population of specialized T lymphocytes composed of different subsets. DX5+NKT cells are
characterized by expression of the NK cell marker DX5 in the context of CD3. However, little is known about the
phenotype and functional capacity of this unique cell population. Therefore, we investigated the expression of
several T cell and NK cell markers, as well as functional parameters in spleen and liver subsets of DX5+NKT cells in
NK1.1- Balb/c mice and compared our findings to NK1.1+ C57Bl/6 mice.
Results: In the spleen 34% of DX5+NKT cells expressed CD62L and they up-regulated the functional receptors
CD154 as well as CD178 upon activation. In contrast, only a few liver DX5+NKT cells expressed CD62L, and they did
not up-regulate CD154 upon activation. A further difference between spleen and liver subsets was observed in
cytokine production. Spleen DX5+NKT cells produced more Th1 cytokines including IL-2, IFN-g and TNF-a, while
liver DX5+NKT cells secreted more Th2 cytokines (e.g. IL-4) and even the Th17 cytokine, IL-17a. Furthermore, we
found inter-strain differences. In NK1.1+ C57Bl/6 mice DX5+NKT cells represented a distinct T cell population
expressing less CD4 and more CD8. Accordingly, these cells showed a CD178 and Th2-type functional capacity
upon activation.
Conclusion: These results show that DX5+NKT cells are a heterogeneous population, depending on the dedicated
organ and mouse strain, that has diverse functional capacity.
Background
Natural killer T (NKT) cells represent a small but
important subset of T lymphocytes with characteristics
of both T and NK cells. They have potent immunoregu-
latory function that reportedly can promote cell-
mediated immunity to tumors and infectious organisms
and, paradoxically, suppress cell-mediated immunity
associated with autoimmune disease and allograft rejec-
tion [1]. In mice, these cells express NK cell markers
such as NK1.1 and CD94, as well as T-cell receptors
(TCR) a/b with a restricted repertoire [2,3]. The invar-
iant T cell receptor a chain Va14-Ja18 with a con-
served CDR3 region is associated with Vb8.2, Vb7 or
Vb2 gene segments [3,4].
In contrast to conventional T-lymphocytes, the TCR
of NKT cells does not interact with antigens presented
by classical major histocompatibility complex (MHC)-
encoded class I or II molecules. Instead, their TCR
recognizes glycolipids presented by CD1d, which is a
MHC class-I-like glycoprotein that belongs to a group
of CD1 molecules associated with b2-microglobulin
[5-7]. CD1d is known to present lipids including glyco-
sylceramides and glycosylphosphatidylinositol [8,9]. Acti-
vation via CD1d initiates the production of both Th1
(IFN) and Th2 cytokines (IL-4, IL-5, IL-13) [10], and
increases the cytolytic activity of NKT cells [11].
NKT cells do not represent a homogeneous popula-
tion. So far, three types of NKT cells have been
described. First, there is an invariant Va14-NKT cell
(iVa14-NKT) also called a type I NKT cell or iNKT cell.
This group can be further differentiated into CD4+ sin-
gle positive and CD4-CD8- double-negative variants.
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Second, a population of CD1d-reactive NKT cells
expressing diverse non-Va14TCRs, referred to as type II
NKT cells, has also been characterized. A third category
has been termed NKT-like cells, which are CD1d-inde-
pendent and express diverse TCRs [2].
Despite many years of NKT cell research, controversy
remains about defining these cells. The expression of
several surrogate markers, such as NK1.1 in C57Bl/6
mice and CD161 in humans, co-expressed with the
TCRa/b, have been frequently used for NKT cell identifi-
cation [2]. There are also NK1.1+ T cells which do not
express the semiinvariant Va14-Ja18 T cell receptor
and are not CD1d-dependent, excluding their considera-
tion as NKT cells.
A common marker for NKT cells in NK1.1- mice
strains is the antibody DX5, which recognizes the a2-
integrin CD49b [12]. DX5 was initially characterized as
a marker for NK cells [13] and more recently DX5 co-
expressing CD3+ lymphocytes have been described [14].
Several studies, including some from our group, revealed
evidence for immunoregulatory properties of these cells
[15-18]. DX5+NKT cells produce Th1 and Th2 cyto-
kines after stimulation like other NKT cells and seem to
play a central role in anti-tumor immunity [13,19].
Recently published studies suggest an immune modula-
tory function of DX5+NKT cells after bone marrow and
solid organ transplantation [20,21]. Although all these
studies describe typical characteristics of NKT cells, Pel-
lecci et al. showed that DX5+ T cell numbers were nor-
mal in CD1d-/- and even in TCR Ja18-/- mice [22].
Therefore, it is more likely that DX5+NKT cells belong
to the third group of NKT-like cells [22,23].
In the present study we have further characterized
DX5+CD3+ T cells referred to as DX5+NKT cells in
NK1.1- (Balb/c) and NK1.1+ (C57Bl/6) mice. For this
purpose DX5+NKT cells were isolated from spleen and
liver and several T and NK cell surface markers as well
as maturation and activation markers were studied by
flow cytometry. Distinct differences could be found
between both subsets and between mouse strains.
Results
T cell marker expression is different between spleen and
liver DX5+NKT cells
Lymphocytes were isolated from spleen and liver of
Balb/c mice by MACS and FACS sorting (Figure 1A).
First, expression of different T cell markers were ana-
lyzed to evaluate which subtype of NKT cells the DX5
+NKT subset belong to. In the spleen of Balb/c mice, 93
± 1.4% of freshly isolated DX5+NKT cells expressed
TCRa/b, with 18 ± 1.2% of cells expressing Vb8.1/8.2
(Figure 1B). Surprisingly, most DX5+NKT cells
expressed CD4 (82 ± 0.85%), with 11 ± 2% expressing
CD8a and CD25. Interestingly, freshly isolated liver DX5
+NKT cells displayed a different receptor pattern. These
cells expressed more Vb8.1/8.2 (36 ± 3.4%, P = 0.0159)
and less CD4 (67 ± 2.6%, P = 0.0079).
Thus far, surface receptor expression was only exam-
ined in freshly isolated cells. Since DX5+NKT cells dis-
play their immunoregulating function especially upon
activation [22], expression patterns after stimulation
were analyzed. For this purpose, splenic and hepatic
mononuclear cells were stimulated for 4 hours with
anti-CD3 and anti-CD28 antibodies. Activation of spleen
DX5+NKT cells from Balb/c mice (Figure 1C) resulted
in a down-regulation of TCRa/b (90 ± 2% vs. 51 ± 2%, P
= 0.004) and an up-regulation of CD25 (14 ± 2.6% vs.
27 ± 3%, P = 0.0411). However, stimulation had little
effect on liver derived cells of Balb/c mice. DX5+NKT
cells revealed an expression pattern similar to that of
freshly isolated cells: there was no down-regulation of
TCRa/b in liver derived DX5
+NKT cells upon
stimulation.
NK cell and activatory markers are expressed differently
in spleen and liver DX5+NKT cells
To further characterize the differences between spleen
and liver DX5+NKT cells, specific antibodies were used
to detect different NK cell types, as well as maturation
and activation markers by flow cytometry. In the spleen
of Balb/c mice (Figure 2A) the NK cell marker CD94
was expressed on 8 ± 1.8% of DX5+NKT cells. Again,
DX5+NKT cells in the liver displayed differences. CD94
was expressed on significantly more cells than in the
spleen (22 ± 3.2%, P = 0.0095). After 4 h stimulation, no
significant change in the NK cell receptor pattern was
observed in splenic or hepatic DX5+NKT cells. As
expected, the NK cell marker NK1.1 was expressed only
on very few splenic (0.5 ± 0.3%) and hepatic (0.8 ±
0.6%) DX5+NKT cells (data not shown).
We also analyzed if the distinct phenotype of spleen
and liver DX5+NKT cells was based on differences in
the maturation status. Therefore, freshly isolated cells
were stained with anti-CD103 and anti-CD62L antibo-
dies (Figure 2B). Spleen DX5+NKT cells were positive
for CD103 in 15 ± 2.4% of cells. In contrast, freshly iso-
lated liver DX5+NKT cells expressed this maturation
marker less frequently (4.5 ± 1.7%, P = 0.014). Freshly
isolated spleen DX5+NKT cells were even more fre-
quently positive for the maturation marker CD62L (34 ±
5.5%) compared to liver DX5+NKT cells (3 ± 2.2%, P =
0.0079). Upon 4 h stimulation, liver DX5+NKT cells dis-
played an increase in CD62L expression (14 ± 1.7%, P =
0.0317), but still significantly less than the spleen subset
(36 ± 4%, P = 0.0028).
Next, differences in activation markers were evaluated.
In freshly isolated DX5+NKT cells the activation marker
CD38 was expressed on approximately 80% of splenic
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and hepatic cells and displayed no significant change
upon stimulation (data not shown). In contrast, upon 4
h stimulation, there was a strong up-regulation of the
activating marker CD154 (3 ± 2.2% vs. 39 ± 5.8%, P =
0.0238) in spleen DX5+NKT cells (Figure 2C). However,
liver DX5+NKT cells did not display a similar up-regula-
tion of CD154 (4 ± 1%, P = 0.0498). Another activating
marker, CD178, was also not significantly expressed on
freshly isolated DX5+NKT cells, but upon 4 h stimula-
tion, there was an up-regulation of CD178 in the spleen
subset (2 ± 1.3% vs. 19 ± 1.4%, P = 0.0087).
Spleen and liver DX5+NKT cells display a distinct cytokine
secretion pattern in Balb/c mice
Results thus far suggest distinct phenotypic differences
between spleen and liver DX5+NKT cells. Next, the pro-
duction of Th1 and Th2 cytokines were compared to
further assess functional differences between these sub-
sets. Lymphocytes were isolated from spleen and liver of
Balb/c mice and cultured for 4, 24 or 48 h in the pre-
sence of anti-CD3 and anti-CD28 antibodies. The cells
were additionally incubated with PMA, ionomycin and
GolgiPlug for intracellular cytokine staining.
As shown in Figure 3, we first stained for Th1 cyto-
kines such as IL-2, IFN-g and TNFa. After 4h stimula-
tion, 33 ± 8% of spleen DX5+NKT cells produced IL-2.
After 24 h, the number of IL-2-producing cells
decreased (0.3 ± 0.1%, P = 0.0238). As expected, liver
DX5+NKT cells showed a distinct Th1 cytokine profile.
After 4 h, lower cell numbers produced IL-2 (11 ± 4.4%,
P = 0.049) compared to spleen cells. Spleen DX5+NKT
cells were also positive for IFN-g after 4 h (46 ± 3.1%),
24 h (40 ± 4.6%) and 48 h (38 ± 6.6%). In contrast, liver
DX5+NKT cells produced less frequently IFN-g after 4 h
Figure 1 FACS analysis of T cell marker from spleen and liver CD3+/DX5+NKT cells in Balb/c mice. DX5+NKT cells were isolated from
spleen and liver of Balb/c mice using MACS and FACS-Sorting. Representative dot plot (A). Expression of different T cell markers revealed distinct
subsets in Balb/c mice. In the spleen, more DX5+NKT cells appeared CD4+, in the liver, they expressed more Vb8.1/8.2 (B). Upon 4 h activation
with anti-CD3 and anti-CD28, spleen DX5+NKT cells displayed a TCRa/b down-regulation, whereas liver DX5+NKT cells did not (C). Results are
given as mean + SEM. Experiments were repeated at least three times (* p < 0.05).
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(24 ± 2.4%, P = 0.0079) and 24 h (14.5 ± 2.2%, P =
0.0095). After 4 h splenic DX5+NKT cells produced also
TNFa (49 ± 0.6%). However, the number of TNFa-pro-
ducing cells decreased after 24 h (22 ± 5.1%, P =
0.0358). Liver DX5+NKT cells again displayed differ-
ences; after 4 h they produced slightly less TNFa com-
pared to the spleen subset (39 ± 4.1%) and, after 24 h,
the number of TNFa-producing cells decreased even
more (4 ± 1.2%, P = 0.0159).
Next, Th2 cytokines such as IL-4, IL-6, IL-10 and IL-13
were analyzed. Only very few spleen DX5+NKT cells pro-
duced IL-4 after 4, 24 and 48 h. However, the number of
IL-4 positive liver DX5+NKT cells increased after 48 h (11
± 1.2%, P = 0.0286). Neither spleen nor liver DX5+NKT
cells were significantly positive for IL-6 at any time point
(data not shown). Spleen DX5+NKT cells showed a signifi-
cant increase in the frequency of IL-10-producing cells after
24 h (13 ± 2.1%) compared to 4 h (0.4 ± 0.2%, P = 0.0187),
and compared to liver DX5+NKT cells after 24 h stimula-
tion (1 ± 0.6%, P = 0.0357). In the spleen the number of IL-
13-producing DX5+NKT cells significantly increased after
48 h compared to 4 h (20 ± 3% vs. 10 ± 1.2%, P = 0.0061),
whereas in liver the number of IL-13 positive DX5+NKT
cells peaked after 4 h compared to 24 h (16 ± 2.1% vs. 3 ±
1.2%, P = 0.0286). Furthermore, we tested for IL-17a as a
Th17-type cytokine. Liver DX5+NKT cells after 4 h more
frequently produced IL-17a (7 ± 1%) compared to the sple-
nic-derived cells (1 ± 0.7%, P = 0.0061); after 24 h, the fre-
quency of liver-derived IL-17a-producing DX5+NKT cells
decreased (0.3 ± 0.3%, P = 0.286).
Figure 2 Activating markers are expressed differently in spleen and liver DX5+NKT cells. Detection of NK cell markers confirmed
differences between spleen and liver subsets of DX5+NKT cells in NK1.1-Balb/c mice. CD94 expression was higher in liver DX5+NKT cells (A).
Furthermore, the liver subset revealed less expression of maturation marker CD103 and CD62L compared to spleen (B). The activating markers
CD154 and CD178 were in both freshly-isolated cell subsets only little expressed (C). Upon stimulation spleen DX5+NKT cells displayed an up-
regulation of CD154, whereas the liver subset did not. Results are given as mean + SEM. Experiments were repeated at least three times (* p <
0.05).
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NK1.1+C57Bl/6 mice reveal distinct surface marker
expression on DX5+NKT cells
Data thus far were obtained using a NK1.1- mouse
strain. These findings were compared to a second
mouse strain known to express NK1.1, C57Bl/6 mice..
Several T cell markers were analyzed. A down-regula-
tion of TCRa/b (65 ± 4.8% vs. 89 ± 2.1%, P = 0.01) was
also observed upon activation of spleen DX5+NKT cells
from C57Bl/6 mice (Figure 4A). Compared to Balb/c,
fewer freshly isolated spleen DX5+NKT cells expressed
CD4 (82 ± 1% vs. 47 ± 1.1%, P = 0.0043), but more
expressed CD8a (11 ± 1.6% vs. 32 ± 0.8%, P = 0.0043).
NK cell markers showed significant differences between
both mouse strains (Figure 4B). In C57Bl/6 mice 33 ±
2.8% of freshly isolated spleen DX5+NKT cells were
stained for CD94 (P = 0.0095) and 39 ± 1% for NK1.1
(P = 0.0022). Compared to Balb/c mice (Figure 4C),
fewer spleen DX5+NKT cells displayed the maturation
marker CD103 (15 ± 1.9% vs. 6 ± 1.6%, P = 0.0030), but
more expressed CD62L (33 ± 5.5% vs. 47 ± 1%, P =
0.0047). In terms of activating markers, both mouse
strains showed little expression of CD154 or CD178 in
freshly isolated DX5+NKT cells (Figure 4D). However,
upon activation, the up-regulation of CD154 (39 ± 5.8%
vs. 13 ± 1.2%, P = 0.0012) was less distinctive in C57Bl/
6 mice, whereas CD178 expression was similar to Balb/c
mice (19 ± 1.4% vs. 18 ± 1.2%).
Cytokine production of spleen DX5+NKT cells is different
in NK1.1-Balb/c and NK1.1+ C57Bl/6 mice
Results have already shown distinct phenotypic differ-
ences in DX5+NKT cells between NK1.1- and NK1.1+
mice strains. Next, cytokine production was compared
to further assess potential functional differences between
these subsets. Lymphocytes were isolated from spleens
of Balb/c and C57Bl/6 mice and cultured for 4, 24 or 48
h. As shown in Figure 5 spleen DX5+NKT cells from
the NK1.1+ mouse strain displayed a distinct Th1 cyto-
kine profile. Compared to NK1.1-Balb/c mice, DX5
+NKT cells less often produced IL-2 (33 ± 8.6% vs. 1 ±
0.5%, P = 0.0357) and TNF-a (49 ± 0.6% vs. 14 ± 8.8%,
P = 0.0167) after 4h; however, production of IFN-g was
similar. In terms of Th2 cytokines, there was also no
significant IL-4 production in spleen DX5+NKT cells
from the NK1.1+ mouse strain. There were some differ-
ences in Th2 cytokine production between NK1.1- and
NK1.1+ mice. After 24 h, spleen DX5+NKT cells in
NK1.1+ C57Bl/6 mice less frequently produced IL-10
(13 ± 2.1% vs. 1 ± 0.3%, P = 0.0357) and IL-13 (14 ± 2.9
vs. 4 ± 0.9%, P = 0.0381). The number of splenic-
Figure 3 Spleen and liver DX5+NKT cells display a distinct cytokine secretion pattern in Balb/c mice. Isolated DX5+NKT cells were
stimulated with antibodies against CD3 and CD28 in the presence of IL-2 for 4, 24 and 48 h, respectively. Control cells were cultured
simultaneously without stimulation. Values were subtracted as background. FACS analysis revealed again distinct differences between spleen and
liver subsets of DX5+NKT cells. Results are given as mean + SEM. Experiments were repeated at least three times (* p < 0.05).
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Figure 4 FACS-Analysis of spleen DX5+NKT cells revealed interstrain differences in several phenotypical markers between NK1.1-Balb/c
and NK1.1+C57Bl/6 mice. In the NK1.1+ mice strain spleen DX5+NKT cells expressed less CD4 but more CD8 (A). Upon activation the TCRa/b
down-regulation was confirmed. In addition to NK.1.1 more spleen DX5+NKT cells in C57Bl/6 mice were positive for CD94 (B). Maturation marker
CD62L was slightly higher expressed in freshly-isolated spleen DX5+NKT cells in C57Bl/6 mice compared to Balb/c, whereas CD103 was less (C).
Functional marker CD154 and CD178 were only little expressed in freshly-isolated spleen DX5+NKT cells in both mice strains (D). Upon
stimulation spleen DX5+NKT cells in NK1.1+ C57Bl/6 mice displayed less up-regulation of CD154 compared to Balb/c. Results are given as mean
+ SEM. Experiments were repeated at least three times (* p < 0.05).
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derived IL-17a-producing DX5+NKT cells was similar in
both mouse strains. Only a few spleen DX5+NKT cells
produced IL17a after 4 h and 24 h.
Discussion
All freshly isolated DX5+NKT cells from NK1.1 deficient
Balb/c mice were positive for TCRa/b, as expected for
type III NKT cells [2,3,24]. Most of them additionally
expressed CD4, and a few expressed CD8a and CD25.
As mentioned in other reports for spleen and thymus
[25], a difference between spleen and liver subsets was
observed. Liver DX5+NKT cells expressed less CD4 and
CD62L. Since expression of CD62L is associated with
naivety or homing to peripheral lymph nodes in iNKT-
cells [26], and CD4 becomes down-regulated after
repeated activation [27], this suggests a higher matura-
tional status of liver DX5+NKT cells in Balb/c mice.
This is supported by the finding that Vb8.2-containing
Va14i TCRs in NKT cells have a higher antigen affinity
than those containing Vb7 or Vb2 [28,29]. Consistent
with the idea of a negative selection, liver DX5+NKT
cells displayed a higher expression of Vb8.1/8.2.
Upon activation, a down-regulation of TCRa/b was
observed in spleen DX5+NKT cells in Balb/c mice. A
decrease of TCRa/b-expression was also reported for
NK1.1+NKT cells [30]. Due to a lack of detection, a
rapid apoptotic death of this cell was initially claimed
upon stimulation [30]. More recently TCRa/b-down-reg-
ulation in spleen and liver NK1.1+NKT cells of C57Bl/6
mice was discovered to be the reason for this assumed
cell disappearance [31,32]. However, our study does not
confirm this finding for liver DX5+NKT cells in Balb/c
mice, supporting evidence that there are distinct subsets
of DX5+NKT cells in the spleen and liver. CD154
expression was also increased upon stimulation. As the
ligand of CD40, CD154 represents a co-stimulatory
Figure 5 Cytokine production by spleen DX5+NKT cells is different in NK1.1-Balb/c compared to the NK1.1+ mice strain C57Bl/6.
Isolated DX5+NKT cells were stimulated with antibodies against CD3 and CD28 for 4, 24 and 48 h. FACS-Analysis revealed a Th1 sided cytokine
profile for spleen DX5+NKT cells of NK1.1+C57Bl/6 mice, whereas spleen DX5+NKT cells of NK1.1-Balb/c mice displayed a pattern with Th1 and
Th2 cytokines. Results are given as mean + SEM. Experiments were repeated at least three times (* p < 0.05).
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molecule and is expressed by activated and regulatory T
cells [33,34]. Furthermore, CD178, the ligand of Fas
responsible for the extrinsic induction of apoptosis (e.g.
expressed on CD8+ cytotoxic T cells) was up-regulated
[35]. This up-regulation was more evident in spleen
than in liver DX5+NKT cells and is also reported for
NK1.1+NKT cells [36]. Taken together, liver DX5+NKT
cells are more mature and display a different activating
phenotype upon stimulation compared to the spleen
subset.
Since NKT cells are supposed to link innate and adap-
tive immunity by rapid secretion of cytokines, including
IFNg, TNFa, IL-4, IL-10, IL-13, GM-CSF and IL-2
[24,37,38], we further assessed differences between
spleen and liver DX5+NKT cells on a functional basis.
Fewer liver DX5+NKT cells in Balb/c mice produced
Th1 cytokines such as IL-2, IFN-g, and TNF-a. In terms
of Th2 cytokines, more liver DX5+NTK cells produced
IL-4, but fewer produced IL-10 compared to the spleen
subset. Charbonnier et al. described an induction of IL-
10 production in liver CD49b+CD4+ T cells by imma-
ture dendritic cell vaccination [18]. However, we did not
confirm this finding for liver DX5+NKT cells in Balb/c
mice after anti-CD3/anti-CD28 stimulation. Collectively,
the limited Th1 cytokine secretion upon stimulation
confirmed the observation that a different activating
phenotype of DX5+NKT cells exists in the liver of Balb/
c mice.
Recently, type I NKT cells have been shown to be cap-
able of producing IL-17, potentially implicating this cell
type in inflammatory conditions [39,40]. We showed
that a subset of DX5+NKT cells in the liver of Balb/c
mice has to be taken into account as an IL-17 producing
cell. These results are consistent with our result regard-
ing a more mature phenotype of liver-derived DX5
+NKT cells, with a different phenotypical profile upon
stimulation compared to the spleen subset.
In NK1.1+ C57Bl/6 mice fewer spleen DX5+NKT cells
revealed expression of CD4, but more of CD8a. These
findings are consistent with data from Pellici et al., who
observed similar differences in C57Bl/6 mice [22]. In
accordance with Conzalez et al., 40-50% of DX5+NKT
cells express NK1.1 [15]. Taking these results together
with the higher CD4 expression in NK1.1-deficient
Balb/c mice, we suggest that these mice compensate for
a reduced number of NK.1.1+NKT cells with a higher
prevalence of CD4+DX5+NKT cells. In contrast to
results from Gonzalez et al. [15], about one-third of
these cells in the spleen of C57Bl/6 mice, and 11% in
Balb/c mice, were CD8+.
Upon activation a down-regulation of TCRa/b was
observed in spleen DX5+NKT cells in Balb/c and in
C57Bl/6 mice, as it has been reported for NK1.1+NKT
cells [30]. Furthermore, upon a 4 h stimulation there
was a notable up-regulation of CD25 in Balb/c versus
C57Bl/6 mice. CD25, the IL-2 receptor a-chain, is pro-
posed to be a phenotypical marker of regulatory T cells
[41-43]. The up-regulation we observed especially for
spleen DX5+NKT cells in Balb/c mice could be either
due to activation and increased receptor expression
based on the regulatory background of DX5+NKT cells
or due to a natural selection because of a higher apopto-
tic resistance in CD4+CD25+ T cells [44]. Another mar-
ker for activation on regulatory T cells is CD154 [34].
CD154 expression was increased upon stimulation in
spleen DX5+NKT cells in Balb/c mice, but was signifi-
cantly less prominent in C57Bl/6 mice. Upon 4 h stimu-
lation, CD178 (ligand of Fas) was similarly up-regulated
[35] on splenic DX5+NKT cells in both mice strains.
However, after 24 h stimulation CD178 expression was
decreased in Balb/c versus C57Bl/6 mice, and CD154
was further up-regulated in Balb/c, but down-regulated
in C57Bl/6 mice (data not shown). These changes sug-
gest a more regulatory CD4+CD25+ phenotype in
NK1.1- Balb/c and a more CD8+ and CD178+ driven
cytotoxic component in the NK1.1+ C57Bl/6 mouse
strain [45].
High IL-2 production by DX5+NKT cells in the early
phase of activation was observed only in Balb/c mice,
further supporting our findings of interstrain differences.
Moreover, splenic DX5+NKT cells in C57Bl/6 mice dis-
played a more one-sided Th1 cytokine profile, with
mostly IFNg and TNFa producing cells, which is also
described for CD8+ T cells [46]. DX5+NKT cells in
Balb/c mice displayed a more polyfunctional cytokine
profile. In the late phase of stimulation, IFNg and TNFa
production decreased and IL-10 and IL-13 secretion
increased. In contrast to liver CD49b+CD4+ cells [18],
and supporting our data regarding splenic DX5+NKT
cells, Kassiotis et al. revealed no IL-10 production for
splenic CD49b+CD4+ T cells in C57Bl/6 mice [47].
Furthermore, Pellicci et al. could not detect any signifi-
cant IL-10 production in DX5+TCRa/b
+CD1d-Tet+ cells
in the same mouse strain [22]. Confirming our finding
and giving again evidence for a difference between both
mouse strains, we showed a significant increase in IL-10
production after 24h stimulation for splenic DX5+NKT
cells in Balb/c mice. Taken together, these results sug-
gesting a more one-sided Th1 cytokine production from
DX5+NKT cells in C57Bl/6 mice confirm their more
CD8 and CD178 expressing phenotype.
Conclusions
In conclusion, our data show that distinct subsets of
DX5+NKT cells exist within NK1.1- Balb/c mice. In the
spleen these cells appear more naive with a higher
CD62L expression and an up-regulation of CD154 and
CD178 upon activation. In contrast, in the liver DX5
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+NKT cells are more mature and display a different reg-
ulatory potency upon stimulation. Furthermore, there
are remarkable inter-strain differences. In NK1.1+
C57Bl/6 mice, fewer DX5+NKT cells are CD4+ and
more are CD8+, confirming their CD178 and Th1-sided
functional behavior upon activation.
Methods
Cell harvesting and isolation
All experiments were approved by the institutional ani-
mal care committee at the University Hospital Regens-
burg. Different lymphocytes subsets were purified from
splenic or hepatic mononuclear cells isolated from Balb/
c mice or C57Bl/6NCrl mice (Charles River Labora-
tories, Wilmington, MA, USA). If necessary, further iso-
lation was performed by magnetic activated cell sorting
(MACS; Miltenyi Biotec, Bergisch Gladbach, Germany)
or by FACS (FACSAria I, BD Bioscience, San Jose, CA,
USA). Briefly, cell suspension of the spleen was prepared
by cutting the tissue into small pieces and gently press-
ing through a 100 μm wire mesh. For preparation of the
liver the portal vein was flushed with 10 ml sodium
chloride until the organ became pale. Then the liver was
cut into small parts and passed through a 100 μm wire
mesh. Hepatic lymphocytes were further isolated by
density gradient centrifugation using 80% and 40% Per-
coll (Biochrom, Berlin, Germany). For further isolation,
DX5+ cells were purified using anti-mouse-DX5+
MicroBeads (Miltenyi Biotec). Cells were passed through
a MACS-column (type LS) attached to a Midi-MACS-
magnet (Miltenyi Biotec). DX5+ cells were labeled with
FITC-conjugated anti-mouse CD3 (clone: 17A2, rat
IgG2b) and PE-conjugated anti-mouse CD49b (clone:
DX5, rat IgM) (all from BD Biosciences) for further
CD3+DX5+ enrichment by FACS, and are referred to as
DX5+NKT cells throughout the study.
Antibodies and flow cytometry
The following reagents were used for cell surface labeling
in multiparameter flow cytometric analysis (FACS Calibur,
BD Bioscience): FITC or Alexa Fluoar 647-conjugated
anti-mouse CD3 (clone: 17A2, rat IgG2b), APC-conju-
gated anti-mouse-CD4 (clone: GK1.5, rat IgG2b), APC-
conjugated anti-mouse-CD8a (clone: 53-6.7, rat IgG2a),
PE-conjugated anti-mouse-CD38 (clone: 90, rat IgG2a),
PE-conjugated anti-mouse-CD49b (clone: DX5, rat IgM),
APC-conjugated anti-mouse-CD62L (clone: MEL-14, rat
IgG2a), PE-conjugated anti-mouse-CD103 (clone: M290,
rat IgG2a), PE-conjugated anti-mouse-CD178 (Fas-Ligand)
(clone: MFL3, hamster IgG1), PE-conjugated anti-mouse-
Vb 8.1, 8.2 TCR (clone: MR5-2, rat IgG2a) all BD Bios-
ciences. APC-conjugated anti-mouse-CD49b (clone: DX5,
rat IgM), FITC-conjugated anti-mouse-CD49b (clone:
DX5, rat IgM) all obtained from Miltenyi Biotec. FITC-
conjugated anti-mouse-CD94 (clone: 18d3, rat IgG2a),
APC-conjugated anti-mouse-CD154 (CD40L) (clone:
MR1, hamster IgG), APC-conjugated anti-mouse-NK1.1
(clone: PK136, mouse IgG2a) all obtained from
eBioscience (San Diego, CA, USA). APC-conjugated anti-
mouse-CD25 (clone: PC61 5.3, rat IgG1), FITC-conjugated
anti-mouse-TCRa/b (clone: HM 3601, hamster IgG) from
Caltag (Towcester, UK).
Activation of DX5+NKT cells
For lymphocyte stimulation, 96 well cell culture plates
(Corning costar, Sigma Aldrich) were coated with anti-
mouse-CD3e (Clone: 145-2C11, BD Biosciences) at 10 μg/
ml and stored overnight at 4°C. Wells were washed twice
with PBS. And up to 1 × 106 isolated lymphocytes from
spleen and liver were plated in 200 μl RPMI culture med-
ium (Biochrom). For activation, 5 μg/ml of anti-mouse-
CD28 (clone: 37.51, BD Biosciences) and 2000 IU/ml IL-2
(Peprotech, Rocky Hill, NJ, USA) were added. Plates were
incubated for the indicated time at 37°C and 5% CO2
Intracellular cytokine staining
4 × 105 DX5+-NKT cells were incubated in 200 μl cul-
ture medium in a 96 well plate as mentioned above.
Additionally, 50 ng/ml PMA (InvivoGen, San Diego,
CA, USA) was added at the beginning, with 750 ng/ml
ionomycin (Sigma-Aldrich, St. Louis, USA) being added
for the last 4h; 1 μg/ml GolgiPlug (BD Bioscience) was
added 2 h before cell harvesting. Culture supernatants
were harvested and stored at -20°C for IFNg ELISA.
Cells were fixed in 1ml Fix/Perm (eBioscience) for 60
min at 4°C. After incubation with permeabilization buf-
fer (eBioscience) cells were stained with PE-conjugated
anti-mouse-cytokine Abs (IL-2, clone: JES6-5H4/IL-4,
clone: BVD4-1D11/IL-6, clone: MP5-20F3/IL-10, clone:
JES5-16E3/IFNg, clone: XMG1.2/TNFa, clone: MP6-
XT22) from BD Bioscience and with PE-conjugated
anti-mouse-Abs (IL-13, clone: eBio13A/IL-17a, clone:
eBio17B7) and FITC-conjugated anti-mouse-IFNg
(clone: XMG1.2) (all eBioscience).
IFNg analysis by Enzyme-Linked Immunosorbent Assay
Stimulation of DX5+NKT cells was confirmed by IFNg
ELISA. IFNg concentration from harvested supernatants
was analyzed using a commercially available sandwich
ELISA kit (BD Bioscience). Tetramethylbenzidine dihy-
drochloride was used for detection. ELISA readings
were determined by OD scanning at 450 nm using an
Emax precision microplate reader from Molecular
Devices (Downingtown, PA, USA).
Statistics
All in vitro experiments were repeated at least 3 times
and data are presented as the mean value ± SEM.
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Statistical analyses were performed using either a stu-
dent’s t-test or the Mann-Whitney-U-test. Differences
were considered significant at P < 0.05.
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